Mobile Technology for Reducing and Preventing Adolescent Suicide

ABSTRACT Suicide is a top two cause of death in the US for adolescents and suicide rates among youth have steadily increased. Despite this, there is a paucity of research on mobile technology designed to reduce suicide attempts among youth.

In this Phase I SBIR application Oui Therapeutics, LLC proposes a project to: 1) Create a beta version of Aviva-Y for youth (ages 13 - 17); and 2) to test the feasibility and acceptability of the beta version of Aviva-Y in a single-group, open-label trial.

Successful execution of the goals of this Phase I project will generate a version of Aviva-Y that is ready to be tested for efficacy with stabilized patients in a clinical trial.

In the long term, this project will have a beneficial impact on the field of youth suicide prevention through the development of mobile technology designed to advance the delivery and dissemination of effective interventions.